APA (7th ed.) Citation

GA, v. H., V, H., NK, S., MP, F., J, R., M, P., . . . P, G. (2016). SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(15), 1723. https://doi.org/10.1200/JCO.2015.66.1181

Chicago Style (17th ed.) Citation

GA, van Hazel, et al. "SIRFLOX: Randomized Phase III Trial Comparing First-Line MFOLFOX6 (Plus or Minus Bevacizumab) Versus MFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 15 (2016): 1723. https://doi.org/10.1200/JCO.2015.66.1181.

MLA (9th ed.) Citation

GA, van Hazel, et al. "SIRFLOX: Randomized Phase III Trial Comparing First-Line MFOLFOX6 (Plus or Minus Bevacizumab) Versus MFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 15, 2016, p. 1723, https://doi.org/10.1200/JCO.2015.66.1181.